Topical Drug Delivery Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The report covers Topical Drugs Market Companies & Growth and the market is segmented by Route of Administration (Dermal, Ophthalmic, Nasal, Oral, and Others), Product (Formulation and Device), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market provides the value (in USD million) for the above-mentioned segments.

Topical Drug Delivery Market Size

Compare market size and growth of Global Topical Drug Delivery Market with other markets in Healthcare Industry

Topical Drug Delivery Market Analysis

The Global Topical Drug Delivery Market is expected to register a CAGR of 8.5% during the forecast period.

The COVID-19 pandemic has posed serious challenges to healthcare systems in Europe and has largely been controlled by drastically cutting down in- and outpatient services for diseases and implementing infection prevention and control measures. The lockdown all over the globe has affected the supply chain of drugs and products. The pandemic has significantly impacted the growth of the topical drug delivery market due to the pandemic situation and restrictions, healthcare settings such as hospitals and specialty clinics were temporary. For instance, an article published by the Dermatological Practical and Conceptual, in January 2021, titled 'Impact of the COVID-19 Pandemic on Dermatology Practice Worldwide: Results of a Survey Promoted by the International Dermoscopy Society (IDS)', it has been observed that the outbreak had a detrimental impact on the majority of dermatology services, leading to a considerable decrease in the amount of time spent consulting with patients and a higher likelihood of missed or delayed diagnoses of skin diseases. Thus, the decreased consulting time spent with patients resulted in a significant drop in patient visits, which has impacted the demand for treatment and services and has negatively impacted the market growth.

However, due to several disadvantages, such as discomfort and needle phobia, the requirement for two doses, the need for trained medical professionals to administer the vaccine, and barriers to international distribution due to the requirement for a cold supply chain, the demand for the transdermal delivery has increased. For instance, according to an article published by SAGE Journal, in August 2021, titled 'Transdermal approaches to vaccinations in the COVID-19 pandemic era', the potential of transdermal approaches, such as microneedle (MN) patches, as an alternative modality for painless medication delivery in COVID-19, has recently been explored. In addition, it has been observed that the successful development of microneedle (MN) patch vaccines has a substantial impact on future vaccine delivery and the decrease of the COVID-19 disease burden. Thus, the increasing clinical studies for topical delivery of vaccines in COVID-19 are expected to increase the market growth over the forecast period.

Certain factors that are propelling the market growth are the high prevalence of skin diseases and technological advancements and innovations.

The rising prevalence of skin diseases such as eczema, psoriasis, acne, cold sore, hives, eczema, and others are the key factors driving the market growth. For instance, according to an article published by StatPearls, in August 2021, titled 'Eczema', it has been observed that the lifetime prevalence of eczema in children is between 15-30% and 2-10% in adults. In addition, as per the same source, about 50% of the patients with severe atopic dermatitis are likely to develop asthma and 75% are likely to develop allergic rhinitis. Additionally, an article published by the Journal of the European Academy of Dermatology and Venerology, in February 2022, titled 'Incidence, prevalence, and risk of acne in adolescent and adult patients with atopic dermatitis: a matched cohort study', it has been observed that in both the general population and atopic dermatitis patients, the 12-month prevalence of acne was 3.7% and 3.9%, respectively. Also, the highest incidence rate of acne was found in atopic dermatitis patients aged 12-18 years, and women with atopic dermatitis had a somewhat greater incidence of acne than men. Furthermore, as per the same source, in comparison to controls, the risk ratio for acne rose with age, reaching 1.41 for patients between the ages of 30 and 39 and 2.07 for patients above the age of 40. Thus, the rising burden of skin diseases among the population is expected to increase the demand for effective and better treatment options which in turn is expected to increase the demand for topical agents, thereby boosting the market growth.

Additionally, the rising technological advancements and innovations are also contributing to market growth. For instance, in March 2022, Galderma launched Twyneo (fixed-dose combination of tretinoin 0.1% and benzoyl peroxide 3%) cream for the topical treatment of acne vulgaris in patients 9 years of age and older. Also, in December 2020, the United States Food and Drug Administration approved Almirall's Klisyri (tirbanibulin) for the topical treatment of actinic keratosis (AK) of the face or scalp.

However, the regulatory scenarios and pricing pressure, and high frequency of product recalls are some factors that are hindering the market growth over the forecast period.

Topical Drug Delivery Industry Overview

The topical drug delivery market is moderately fragmented. The major players in the topical drug delivery market include Bayer AG, Cipla, Viatris, GlaxoSmithKline PLC, Galderma Holding SA, Novartis AG, Med Pharm, Johnson & Johnson (Janssen Pharmaceutical), and Hisamitsu Pharmaceuticals.

Topical Drug Delivery Market Leaders

  1. Hisamitsu Pharmaceuticals

  2. Bayer AG

  3. Novartis AG

  4. Galderma Holding SA

  5. GlaxoSmithKline PLC

  6. *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF

Topical Drug Delivery Market News

  • In July 2022, the United States Food and Drug Administration approved Aleor Dermaceuticals, a subsidiary of Alembic Pharmaceuticals, Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Topical Gel, 3%, for the topical treatment of actinic keratoses.
  • In July 2022, the United States Food and Drug Administration approved Arcutis Biotherapeutics's New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. ZORYVE provides rapid clearance of psoriasis plaques and reduces itch in all affected areas of the body.

Topical Drug Delivery Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 High Prevalence of Skin Diseases
    • 4.2.2 Technological Advancements and Innovations
  • 4.3 Market Restraints
    • 4.3.1 Regulatory Scenario and Pricing Pressure
    • 4.3.2 High Frequency of Product Recalls
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers/Consumers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value in USD million)

  • 5.1 By Route of Administration
    • 5.1.1 Dermal
    • 5.1.2 Ophthalmic
    • 5.1.3 Nasal
    • 5.1.4 Oral
    • 5.1.5 Others
  • 5.2 By Product
    • 5.2.1 Formulation
    • 5.2.1.1 Solid
    • 5.2.1.2 Semi-Solid
    • 5.2.1.2.1 Creams
    • 5.2.1.2.2 Ointment
    • 5.2.1.2.3 Others
    • 5.2.1.3 Liquid
    • 5.2.2 Device
    • 5.2.2.1 Inhaler
    • 5.2.2.2 Patch
  • 5.3 By Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia Pacific
    • 5.3.4 Middle-East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bayer AG
    • 6.1.2 Cipla Limited
    • 6.1.3 Viatris
    • 6.1.4 Glaxosmithkline PLC
    • 6.1.5 Hisamitsu Pharmaceuticals
    • 6.1.6 Johnson & Johnson (Janssen Pharmaceutical)
    • 6.1.7 Medpharm
    • 6.1.8 Galderma Holding SA
    • 6.1.9 Novartis AG
    • 6.1.10 Bausch Health Companies Inc.
    • 6.1.11 3M
    • 6.1.12 Pfizer Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Topical Drug Delivery Industry Segmentation

As per the scope of the report, topical drug delivery is a medication that is topically applied to a particular place or on the body. Topical drug delivery systems are preferably used to treat common skin diseases such as bacterial infections, fungal infections, inflammations, acne, psoriasis, hair, and skin problems. The Topical Drug Delivery Market is Segmented by Route of Administration (Dermal, Ophthalmic, Nasal, Oral, and Others), Product (Formulation and Device), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Route of Administration Dermal
Ophthalmic
Nasal
Oral
Others
By Product Formulation Solid
Semi-Solid Creams
Ointment
Others
Liquid
Device Inhaler
Patch
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Topical Drug Delivery Market Research FAQs

What is the current Global Topical Drug Delivery Market size?

The Global Topical Drug Delivery Market is projected to register a CAGR of 8.5% during the forecast period (2025-2030)

Who are the key players in Global Topical Drug Delivery Market?

Hisamitsu Pharmaceuticals, Bayer AG, Novartis AG, Galderma Holding SA and GlaxoSmithKline PLC are the major companies operating in the Global Topical Drug Delivery Market.

Which is the fastest growing region in Global Topical Drug Delivery Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Topical Drug Delivery Market?

In 2025, the North America accounts for the largest market share in Global Topical Drug Delivery Market.

What years does this Global Topical Drug Delivery Market cover?

The report covers the Global Topical Drug Delivery Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Topical Drug Delivery Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Topical Drug Delivery Industry Report

Statistics for the 2025 Global Topical Drug Delivery market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Topical Drug Delivery analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Topical Drug Delivery Market Report Snapshots

Topical Drug Delivery Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)